Related references
Note: Only part of the references are listed.Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn's Disease
David Drobne et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission
Erik Mooiweer et al.
JOURNAL OF CROHNS & COLITIS (2015)
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Tailoring anti-TNF therapy in IBD: drug levels and disease activity
Shomron Ben-Horin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
T. Molnar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Therapeutic drug monitoring of biologics for inflammatory bowel disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2012)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
A. W. G. Waugh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
